Edition:
United States

Arsanis Inc (ASNS.OQ)

ASNS.OQ on NASDAQ Stock Exchange Global Market

1.66USD
18 Sep 2018
Change (% chg)

-- (--)
Prev Close
$1.66
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
25,329
52-wk High
$27.83
52-wk Low
$1.65

Chart for

About

Arsanis, Inc. is a biopharmaceutical company. The Company is focused on the discovering and developing monoclonal antibodies (mAbs) for the targeted immunotherapy of serious infections. The Company's mAbs focus on specific pathogens and pathogenic processes. Its product pipeline includes ASN100, ASN200, ASN300, ASN400 and... (more)

Overall

Beta: --
Market Cap(Mil.): $23.76
Shares Outstanding(Mil.): 14.32
Dividend: --
Yield (%): --

Financials

  ASNS.OQ Industry Sector
P/E (TTM): -- 103.50 32.14
EPS (TTM): -3.45 -- --
ROI: -117.19 1.52 12.66
ROE: -- 0.25 14.84

BRIEF-Arsanis Posts Qtrly Loss Per Share $0.74

* ASN100 PHASE 2 TRIAL INTERIM ANALYSIS RESULTS EXPECTED IN LATE JUNE

May 10 2018

BRIEF-Arsanis Inc - Out Licenses Preclinical Stage E. Coli Monoclonal Antibodies

* BB100 SECURED EXCLUSIVE,WORLDWIDE PRECLINICAL DEVELOPMENT LICENSE, OPTION TO DEVELOPMENT, COMMERCIALIZATION LICENSE, TO MABS TARGETING E. COLI Source text for Eikon: Further company coverage: (Reuters.Brief@thomsonreuters.com)

Apr 04 2018

Earnings vs. Estimates